A prospective, single arm, non-randomized pivotal study to evaluate the safety and performance of the Xeltis hemodialysis access graft in subjects older than 18 years with end-stage renal disease, who plan to undergo hemodialysis for at least the first 6 months after study access creation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
120
The aXess graft is a sterile, regenerative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
AZ Sint Jan Brugge
Bruges, Belgium
ZOL Genk
Genk, Belgium
Primary patency rate
Defined as the interval between vascular access creation and the first intervention to maintain or restore patency.
Time frame: 6 months
Freedom from device-related SAE during the first 6 months
Time frame: up to 6 months
Implantation success rate
Defined as a technically successful aXess graft implantation in the planned configuration, free from kinking and tension in the anastomoses. This is assessed at the procedure day itself.
Time frame: 1 day, from moment of implant until end of procedure day
Patency (primary, primary assisted, secondary, and functional) rates
Primary patency: Defined as the interval between vascular access creation and the first intervention to maintain or restore patency. Assisted primary patency: Defined as the interval between vascular access creation and the first occlusion (thrombosis), including interventions (operative or endovascular) aimed to maintain the functionality the vascular access. Secondary patency: Defined as the interval between vascular access creation and abandonment with or without interventions (operative or endovascular) aimed to maintain the functionality the vascular access, including occurrence of a censored event (death, change of modality, loss of follow-up). Functional patency: Defined as the interval between first cannulation and abandonment, including occurrence of a censored event (death, change of modality, loss of follow-up).
Time frame: 6, 12, 18, 24 and 60 months
Time (expressed in months) to first intervention and to access abandonment
Time frame: 60 months
Rate of access-related interventions required to achieve/maintain patency
Time frame: 6, 12, 18, 24, and 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
UZ Ghent
Ghent, Belgium
Universitätsklinikum Köln
Cologne, Germany
LAIKO General Hospital of Athens
Athens, Greece
University General Hospital of Patras
Pátrai, Greece
Ospedali Riuniti Torrette di Ancona
Ancona, Italy
Policlinico di Bari
Bari, Italy
Policlinico di Sant'Orsola
Bologna, Italy
Università degli studi di Padova / Azienda ospedaliera di Padova
Padua, Italy
...and 12 more locations
Freedom from device-related SAE
Time frame: 12, 18, 24, and 60 months
Rate of access site infections
Time frame: 6, 12, 18, 24, and 60 months
Proportion of hemodialysis sessions completed via central venous catheter (CVC) during the first 12 months of access creation and access cannulation, irrespective of access abandonment
Time frame: 12 months
Time to first cannulation
Time frame: 12 months
Following first cannulation, number of days with CVC in situ (catheter contact time) during the first 12 months, irrespective of access abandonment
Time frame: 12 months